Irbesartan Doc Generici

Irbesartan, the active ingredient in Irbesartan Doc Generici, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to lower elevated blood pressure and to protect kidney function in patients with diabetic kidney disease.

GNH USA supplies Irbesartan Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage conditions related to high blood pressure and kidney disease. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes. - Chronic kidney disease with proteinuria: lowers protein excretion and supports renal preservation.

Irbesartan is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: light‑headed feeling, especially after standing quickly. - Headache: mild to moderate intensity. - Fatigue: unusual tiredness without exertion. - Upper respiratory tract infection: nasal congestion or sore throat. - Hyperkalemia: elevated blood potassium levels detected on lab testing.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Acute renal failure: sudden decline in kidney function. - Severe hyperkalemia: potassium levels that may cause cardiac arrhythmia. - Hepatic injury: signs of liver dysfunction such as jaundice. - Hypotension: markedly low blood pressure causing faintness.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Serum potassium measurement: monitor especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity risk. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: combined use can cause severe hyperkalemia and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Lithium: concurrent use can raise lithium levels, risking toxicity. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations. - Other antihypertensives: additive blood‑pressure lowering effect, monitor for hypotension.